# Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes

> **NCT05834868** · PHASE3 · COMPLETED · sponsor: **Tonghua Dongbao Pharmaceutical Co.,Ltd** · enrollment: 1040 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** THDB0206 Injection
- **DRUG:** Insulin Lispro Injection

## Key facts

- **NCT ID:** NCT05834868
- **Lead sponsor:** Tonghua Dongbao Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-06
- **Primary completion:** 2024-12-10
- **Final completion:** 2024-12-31
- **Target enrollment:** 1040 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05834868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05834868, "Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05834868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*